Join us live on June 3 for a webinar on how NAMs like 3D in vitro kidney models are reshaping CKD research and drug development. Learn how these immune-competent human-relevant systems can close the gap between lab and clinic. 🔗 Register: https://t.co/gVszDVPhy9 #NAMs

Looking for a physiologically relevant gut model? MIMETAS’ 3D human gut models recreate key intestinal features, combining epithelium + perfused vasculature, stroma & immune components for more predictive barrier, ADME, toxicity & inflammation studies. https://t.co/iQ5q8wBfBB

❓How can we better model the human blood-brain barrier for CNS disease and drug development? From tight barrier formation to applications in stroke, neuroinflammation, toxicity testing, small-molecule transport, and antibody transcytosis: https://t.co/cjkH6Y1iiE

🚀 It’s here! We’re excited to unveil a fully redesigned website for MIMETAS. Built around how you explore science - from models and technology to screening, analysis, and ready-to-use tissues - all in one intuitive place. See for yourself: https://t.co/4uB0YUm44O #OrganOnAChip

🎓 Congrats to Dr. Murillo Bernardi on his successful PhD defense! His thesis, “From Chick to Chip - Novel models to bridge in vitro and in vivo kidney research” presents years of work on advancing predictive kidney models at UMC Utrecht and MIMETAS. #PhDDefense #MIMETAS

In this app note, learn how MIMETAS’ OrganoReady® Blood Vessel models enable high-throughput, human-relevant toxicity screening in 3D microfluidic blood vessel systems, - supporting the development of safer therapeutics and better treatment strategies. 🔗 https://t.co/KKQndsHD7v

New publication from @BIOASTER! Using the OrganoPlate® platform and OrganoTEER® device, they built an immunocompetent intestinal model showing that Bifidobacterium infantis and Lacticaseibacillus rhamnosus GG protect the gut barrier from inflammation. https://t.co/ChMsuuV9dg

⏰Join us for a webinar on Ready-to-Use Colon Organoids for Multimodal Toxicity Assessment. • Quantify transporter expression & function • Gain morphological insights via Spark® Cyto imaging • Scale workflows for reproducible preclinical evaluation https://t.co/bwwNYVYguO

Something big is coming. A new way to explore and experience MIMETAS' innovation. Stay tuned. 👀

🗓️ Only 1 week to go! Join our live webinar to learn how physiologically relevant gut organoid models, combined with advanced readout platforms, can elevate the predictive power of preclinical research. Register now: https://t.co/1FV5JoTzP9 #Organoids #PreclinicalResearch

🎓 Congratulations to Dr. Bart Kramer! Our Scientific Project Lead has successfully defended his PhD on “Vasculature and Flow in Microfluidic Systems.” His work advances organ-on-a-chip models by bringing vascular flow closer to real human biology. 👏 #OrganOnAChip #PhD

Our Territory Manager, Nick Saites is at #NAVBO2025 in Cape Cod! He presented on: 🧬 Perfusable vascular networks using a gravity-driven microfluidic system 🧠 High-throughput BBB-on-a-chip model for drug discovery Download the poster: https://t.co/lMzgHxtFCJ

Yesterday, we welcomed visitors from @GemeenteLeiden, @LeidenBSP, and @NBTC — part of the #NewDutch network — to MIMETAS! 🇳🇱 The visit spotlighted Dutch innovation in cancer research, with lab tours showcasing how our Organ-on-a-Chip tech accelerates better therapies.

Traditional in vitro models can’t fully capture human gut complexity. Join Christian Oberdanner (Tecan) & Sara Shafiei (MIMETAS) for a webinar on Nov 4 to explore how gut organoid models + advanced readouts are redefining preclinical research. Register: https://t.co/XHVgHJcb1w

Our Early Stage Researcher Tomás Coimbra is at FIGON Dutch Medicines Days (Oct 8–9)! ✨ He’s presenting: “A scalable human primary liver model to study cell-cell interactions.” 📍 Poster sessions: 12:30–14:00, both days. Don’t miss it if you’re attending!

In this customer publication, researchers used MIMETAS’ OrganoReady® Colon Organoid and OrganoTEER® to show how a Lactobacillaceae-derived postbiotic protects the gut barrier, supports recovery, and reduces inflammation. Read it here:

GI toxicity is a major side effect of cancer therapies. Our 3D Colon Organoid Model brings human relevance + high-throughput screening to better predict drug-induced GI toxicity. Explore our poster 👉 https://t.co/qd4YPrnHIW #Toxicology #Organoids #DrugDevelopment #Innovation

📸 Proud moment! Our VP of Biology, Henriette Lanz, presented at #GoodbyeFlatBiology. She shared insight on using patient-derived 3D tumor models to support cell therapy programs by replicating the complex tumor-microenvironment in vitro. #OrgansOnChips #FutureOfBiology

🔬Today on #WorldCancerResearchDay, we recognize the need for research that leads to better cancer treatments and outcomes. At MIMETAS, we support scientists with human 3D models that improve translation from lab to clinic. #CancerResearch #3DCellCulture #Oncology

🚨 #EuroTox Day 2! Meet MIMETAS’ Brian Duggan & Debarati Shome as they present two posters on Risk Prediction and Assessment using NAMs and An Assay-Ready ASC-Derived Colon Organoid Model for Evaluating Therapy-Induced Gastrointestinal Toxicity. #EuroTox2025

📍 We’re at #EuroTox2025! Meet MIMETAS experts Debarati Shome & Brian Duggan to explore how our organ-on-a-chip tech is shaping safety testing & drug development. Don’t miss our posters + connect with us in Athens! #OrganOnAChip #FutureOfToxicology #Innovation